Johan H. Melendez

Johan H. Melendez


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Sexually Transmitted Diseases
Verified
Journal Article
Closed access
JMJohan H. Melendez
Johan H. Melendez
MHMatthew M. MBChB Hamill
Matthew M. MBChB Hamill
GAGretchen S. Ma Armington
Gretchen S. Ma Armington
CGCharlotte A. DrPH Gaydos
Charlotte A. DrPH Gaydos
YMYukari C. Manabe
Yukari C. Manabe

14 May 2021 in Sexually Transmitted Diseases
Verified
Journal Article
Open access
CGCharlotte A. Gaydos
Charlotte A. Gaydos
YMYukari C. Manabe
Yukari C. Manabe
JMJohan H. Melendez
Johan H. Melendez
Background: Point-of-care (POC) tests enable immediate diagnosis and targeted treatment of sexually transmitted infections (STIs), which could accelerate control of ongoing epidemics. Although older nucleic acid amplification tests have improved the accuracy of laboratory-based tests for STIs, newer POC tests can facilitate control efforts. We sought to review the performance and time to result of POC assays for STIs in the last 10 years. Methods: The authors performed a PubMed, US National Library of Medicine, National Center for Biotechnology Information search for POC tests for STIs or sexually transmitted diseases. Results: Diagnostic technology for POC assays for STIs has achieved high sensitivity and specificity (>90%) using recent molecular advances in the last 10 years. Three POC tests for chlamydia and gonorrhea and 2 for trichomonas have been cleared by the Food and Drug Administration and can provide rapid results during the clinical encounter. Two POC assays for syphilis are now cleared by the Food and Drug Administration. Other similar POC assays are in development. These “fast followers” have faster time to result and will extend the diagnostic armamentarium at POC. Conclusions: New technology has improved the performance accuracy of STI POC diagnostics. Innovation in device format has resulted in accurate POC assays, which can decrease the time to result and accelerate the detection and treatment of STIs during the clinical encounter. The full implementation potential of these newer tests will depend on the ability of these tests to achieve Clinical Laboratory Improvement Amendments–waived status so they can be performed by nonlaboratorians with no previous training.

1 February 2022 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
KHKuangwen Hsieh
Kuangwen Hsieh
JMJohan H. Melendez
Johan H. Melendez
CGCharlotte A. Gaydos
Charlotte A. Gaydos
TWTza-Huei Wang
Tza-Huei Wang
Toward tackling the ongoing epidemic of sexually transmitted infections, this review aims to bridge the gap between researchers who develop nucleic acid amplification-based point-of-care tests and end-users who need such tests.

1 November 2016 in Contraception
Verified
Journal Article
Closed access
ATAndrea Ries Thurman
Andrea Ries Thurman
TJTerry Jacot
Terry Jacot
JMJohan H. Melendez
Johan H. Melendez
TKThomas Kimble
Thomas Kimble
MSMargaret Snead
Margaret Snead
CMChristine Mauck
Christine Mauck

17 August 2018 in Antibiotics
Verified
Journal Article
Open access
PDF file
JMJohan H. Melendez
Johan H. Melendez
JHJustin Hardick
Justin Hardick
MBMathilda Barnes
Mathilda Barnes
KPKathleen R. Page
Kathleen R. Page
CGCharlotte A. Gaydos
Charlotte A. Gaydos
The increasing rates of gonorrhea infections and the global emergence and spread of multi-drug-resistant Neisseria gonorrhoeae (NG) threaten the successful management of gonorrhea. In the era of nucleic acid amplification tests (NAATs), surveillance projects are urgently needed to monitor prevalence and trends in the antimicrobial susceptibility of NG. In this study, we retrospectively determined the susceptibility profile of NG isolates to previously and currently prescribed antimicrobials. NG isolates collected in Baltimore, Maryland between January and October 2016 were evaluated by the E-test method and/or molecular methods for susceptibility to ceftriaxone, azithromycin, ciprofloxacin, tetracycline, gentamicin, and penicillin. One-hundred and forty-three NG isolates from African-American males (98.6%), primarily heterosexual (88.8%), ranging in age from 15 to 69 years of age were included in the study. Ciprofloxacin resistance was observed in 44.1% of isolates. Plasmid-mediated resistance to penicillin and tetracycline resistance was detected in 22.4% and 10.1% of isolates, respectively. Three isolates (2.1%) displayed high-level resistance to azithromycin (minimum inhibitory concentration (MIC) > 256 μg/mL). Forty-three percent of isolates were resistant or had decreased susceptibility to three antimicrobials (ciprofloxacin, tetracycline, and penicillin). All isolates were susceptible to ceftriaxone and gentamicin. Overall, the epidemiology of antimicrobial resistant NG in Baltimore continues to evolve, and the emergence of azithromycin resistance in this population emphasizes the need for continued sentinel surveillance programs to monitor susceptibility trends and aid in treatment recommendations.

5 December 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
JMJohan H. Melendez
Johan H. Melendez
VEVonetta L Edwards
Vonetta L Edwards
ATAdamaris Muniz Tirado
Adamaris Muniz Tirado
JHJustin Hardick
Justin Hardick
AMAditya Mehta
Aditya Mehta
HTHervé Tettelin
Hervé Tettelin
Antimicrobial resistance in Neisseria gonorrhoeae (Ng) has severely reduced treatment options, including azithromycin (AZM), which had previously been recommended as dual therapy with ceftriaxone. This study characterizes the emergence of high-level resistance to AZM (HLR-AZM) Ng in Baltimore, Maryland, USA, and describes the global evolution of HLR-AZM Ng. Whole genome sequencing (WGS) of 30 Ng isolates with and without HLR-AZM from Baltimore was used to identify clonality and resistance determinants. Publicly available WGS data from global HLR-AZM Ng ( n = 286) and the Baltimore HLR-AZM Ng ( n = 3) were used to assess the distribution, clonality, and diversity of HLR-AZM Ng. The HLR-AZM Ng isolates from Baltimore identified as multi-locus sequencing typing sequence type (ST) 9363 and likely emerged from circulating strains. ST9363 was the most widely disseminated ST globally represented in eight countries and was associated with sustained transmission events. The number of global HLR-AZM Ng, countries reporting these isolates, and strain diversity increased in the last decade. The majority (89.9%) of global HLR-AZM Ng harbored the A2059G mutation in all four alleles of the 23S rRNA gene, but isolates with two or three A2059G alleles, and alternative HLR-AZM mechanisms were also identified. In conclusion, HLR-AZM in Ng has increased in the last few years, with ST9363 emerging as an important gonococcal lineage globally. The 23S rRNA A2059G mutation is the most common resistance mechanism, but alternative mechanisms are emerging. Continued surveillance of HLR-AZM Ng, especially ST9363, and extensively drug-resistant Ng is warranted.